

Candidate for Director-at-Large, Controlled Release Society (CRS)

Candidate Name: Jai Prakash

Affiliation: Professor and Group leader,
Radboud University Medical Centre,
Nijmegen, The Netherlands. Email: jai.prakash@radboudumc.nl



Vision Statement

Having been closely engaged with the Controlled Release Society (CRS) since my graduation, and with over two decades of experience in drug delivery research and translation, my vision is to help position CRS as the global anchor for innovation in drug delivery and translational nanomedicine.

Throughout my career—as a scientist in both academia and industry, founder of a start-up company and the NanoTME Conference, and former president of the BeNeLux CRS local chapter—I have consistently worked at the interface of science, entrepreneurship, and community building.

CRS has long been the intellectual home for pioneering science and an inspiring platform for young scientists in drug delivery, nanomedicine, and bioengineering. I aim to further strengthen its role as the premier global platform by fostering deeper and more strategic integration across disciplines—bringing together biomaterials scientists, engineers, clinicians, immunologists, regulatory experts, entrepreneurs, and industry leaders—to address emerging therapeutic challenges, including complex diseases and advanced biologics.

As a professor dedicated to mentoring young talent and promoting interdisciplinary research, I am deeply committed to empowering the next generation of scientists and innovators. By cultivating inclusive leadership, strengthening academia–industry partnerships, and expanding entrepreneurial engagement within CRS, we can ensure that the Society remains not only scientifically excellent, but also globally influential and future-oriented.

Strategic goals

- 1. Empower early-career researchers:** Expand mentorship programs, networking platforms, and leadership opportunities to support the next generation scientists.
- 2. Enhance global and chapter engagement:** Build stronger connections between CRS chapters to increase global participation, diversity, and cross-regional collaboration.
- 3. Strengthen translational networks:** Promote initiatives that bridge academia, industry, and regulatory stakeholders to accelerate the translation of drug delivery technologies into clinical practice.
- 4. Expand emerging frontiers:** Embraces cutting-edge areas such as immunoengineering, advanced 3D models, and precision therapeutics.
- 5. Increase societal and policy visibility:** Advocate for the recognition of drug delivery science as a foundation of modern medicine through outreach, partnerships, and policy engagement.

As Director-at-Large, I will bring strategic leadership, translational perspective, and an inclusive global mindset to advance CRS's scientific excellence and long-term impact.